$FTH News

Faeth Therapeutics Q2 EPS $(2.84) Beats $(3.29) Estimate

Raymond James Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $56

Oppenheimer Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $60

Citizens Initiates Coverage On Faeth Therapeutics with Market Outperform Rating, Announces Price Target of $51

BTIG Reiterates Buy on Faeth Therapeutics, Maintains $55 Price Target

Baird Initiates Coverage On Faeth Therapeutics with Outperform Rating, Announces Price Target of $57

Sensei Biotherapeutics Changes Corporate Name To Faeth Therapeutics, Ticker To FTH, Effective June 16; Appoints Anand Parikh Chairman, President And CEO; Brian Stephenson Appointed CFO, Effective June 12

BTIG Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $55

Cantor Fitzgerald Initiates Coverage On Sensei Biotherapeutics with Overweight Rating

LUCID CAPITAL MARKETS Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $50

Citigroup Initiates Coverage On Sensei Biotherapeutics with Buy Rating, Announces Price Target of $55

Sensei Biotherapeutics Q1 EPS $(131.45) Misses $(0.62) Estimate

Sensei Biotherapeutics Says First Patient Dosed In Study FTH-PIK-101, Phase 1b/2 Trial Of PIKTOR In Patients With HR+/HER2- Advanced Breast Cancer

Sensei Biotherapeutics Files Prospectus To Register 24.9M Shares For Resale By Selling Shareholders

Sensei Biotherapeutics Q4 EPS $(3.74) Beats $(4.11) Estimate

Sensei Biotherapeutics Grants New Employee Option To Purchase 166,435 Shares At $29.37 Under Nasdaq Inducement Rule

Sensei Biotherapeutics Grants New Employee Option To Purchase 166,435 Shares At $29.37 Under Nasdaq Inducement Rule

Sensei Biotherapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sensei Biotherapeutics, Inc. (SNSE) Faeth Therapeutics, Inc. - M&A Call - Slideshow

Sensei Biotherapeutics Stock Soars 230% After Faeth Deal